Photo of Akash Patnaik,  MD, PhD

Akash Patnaik, MD, PhD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-9177


apatnaik@bidmc.harvard.edu

Akash Patnaik, MD, PhD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Attending Physician, Medicine-Hematology/Oncology, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

My current laboratory research efforts are focused on the discovery of novel therapeutic targets for advanced prostate cancer. I am interested in devising approaches to determine the key upstream activators of signaling pathways important in advanced prostate cancer, and to determine which drugs that target components of the PI3K and MAPK pathway or its upstream activators, are likely to be effective based on the mutational state of the cancer. We are currently evaluating several targeted agents in genetically engineered endogenous mouse models of prostate cancer, in parallel to human clinical trials. The long-term goal is to use mouse models with defined genetic mutations to guide selection of patients that will benefit most from the use of these compounds, thus moving the field in the direction of “personalized medicine”. In addition, each drug’s efficacy as a single agent and/or in combination with other targeted therapies will also be explored in mouse models. In parallel to the preclinical trials in authocthonous mouse models of prostate cancer, we are also designing rational early Phase I/IIclinical trials, with newly emerging therapies that target different components of these "driver" pathways.

Publications

Powered by Harvard Catalyst
  • González-Billalabeitia E, Seitzer N, Song SJ, Song MS, Patnaik A, Liu XS, Epping MT, Papa A, Hobbs RM, Chen M, Lunardi A, Ng C, Webster KA, Signoretti S, Loda M, Asara JM, Nardella C, Clohessy JG, Cantley LC, Pandolfi PP. Vulnerabilities of PTEN-p53-deficient prostate cancers to compound PARP/PI3K inhibition. 2014. PubMed
  • Fendt SM, Bell EL, Keibler MA, Davidson SM, Wirth GJ, Fiske B, Mayers JR, Schwab M, Bellinger G, Csibi A, Patnaik A, Blouin MJ, Cantley LC, Guarente L, Blenis J, Pollak MN, Olumi AF, Vander Heiden MG, Stephanopoulos G. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res 2013; 73:4429-38. PubMed
  • Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44. PubMed
  • Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat Genet 2013; 45:747-55. PubMed
  • Zadra G, Priolo C, Patnaik A, Loda M. New Strategies in Prostate Cancer: Targeting Lipogenic Pathways and the Energy Sensor AMPK. Clin Cancer Res 2010; 16:3322-8. PubMed
  • Shaywitz AJ,Courtney KD,Patnaik A,Cantley LC. PI3K enters beta-testing. Cell Metab 2008; 8:179-81. PubMed
  • Spidel JL, Craven RC, Wilson CB, Patnaik A, Wang H, Mansky LM, Wills JW. Lysines close to the Rous sarcoma virus late domain critical for budding. J Virol 2004; 78:10606-16. PubMed
  • Patnaik A, Wills JW. In vivo interference of Rous sarcoma virus budding by cis expression of a WW domain. J Virol 2002; 76:2789-95. PubMed
  • Patnaik A, Chau V, Li F, Montelaro RC, Wills JW. Budding of equine infectious anemia virus is insensitive to proteasome inhibitors. J Virol 2002; 76:2641-7. PubMed
  • Patnaik A, Chau V, Wills, JW.. Ubiquitin is a component of the retrovirus budding machinery Proc Natl Acad Sci U S A 2000; 97:13069-74.